Traduction de «2009 annual report and conform » (Néerlandais → Français) :

The Group’s principal accounting policies are set out in note 1 to the Consolidated Financial Statements in the 2009 Annual Report and conform with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board.
Les principales normes comptables appliquées par le Groupe sont exposées à la note 1 des Comptes consolidés figurant dans le Rapport annuel 2009 et satisfont aux normes dites International Financial Reporting Standards (IFRS) établies par l’International Accounting Standards Board.

The Group’s principal accounting policies are set out in note 1 to the Consolidated Financial Statements in the 2009 Annual Report and conform with International Financial Reporting Standards (IFRS).
Les principales normes comptables appliquées par le Groupe sont exposées à la note 1 des Comptes consolidés figurant dans le Rapport annuel 2009 et satisfont aux normes International Financial Reporting Standards (IFRS).

See note 20 in the Group’s Consolidated Financial Statements in the 2009 Annual Report for a summary of major legal proceedings. The following is a non-exhaustive list relating to some cases reported in the 2009 Annual Report and includes information as of the 2009 fourth quarter:
Pour un résumé des litiges majeurs, prière de consulter la note 20 des Comptes consolidés du Groupe figurant dans le rapport annuel 2009.La liste suivante, non exhaustive, passe en revue quelquesuns des cas cités dans le Rapport annuel 2009 et contient les informations disponibles au quatrième trimestre 2009.

The principal accounting policies of Novartis are set out in note 1 to the Consolidated Financial Statements in the 2008 Annual Report and conform with International Financial Reporting Standards (IFRS).
Les principales normes comptables appliquées par Novartis sont exposées dans l’annexe 1 aux comptes consolidés du Groupe figurant dans le Rapport annuel 2008 et satisfont aux normes International Financial Reporting Standards (IFRS).

The principal accounting policies of Novartis are set out in note 1 to the consolidated financial statements in the 2008 Annual Report and conform with International Financial Reporting Standards (IFRS).
Les principales normes comptables appliquées par Novartis sont exposées dans l’annexe 1 aux comptes consolidés du Groupe figurant dans le Rapport annuel 2008 et satisfont aux normes International Financial Reporting Standards (IFRS).

These Condensed Interim Consolidated Financial Statements for the three- and ninemonth periods ended September 30, 2009, were prepared in accordance with International Accounting Standard 34 Interim Financial Reporting and accounting policies set out in the 2008 Annual Report published on January 28, 2009.
Les Comptes intermédiaires consolidés simplifiés pour les périodes de trois et de neuf mois se terminant le 30 septembre 2009 ont été établis conformément à la norme comptable internationale 34 Information financière intermédiaire et aux normes comptables décrites dans le rapport annuel 2008 publié le 28 janvier 2009.

The Group’s principal accounting policies are set out in note 1 to the Consolidated Financial Statements in the 2008 Annual Report and conform with International Financial Reporting Standards (IFRS).
Les principales normes comptables appliquées par le Groupe sont exposées dans l’annexe 1 aux Comptes consolidés figurant dans le Rapport annuel 2008 et satisfont aux normes International Financial Reporting Standards (IFRS).

NB De technische definities zijn opgenomen in deel IV van het jaarverslag 2009 van het RIZIV. [http ...]
N.B. Les définitions techniques se trouvent dans le rapport annuel 2009 de l’INAMI, partie IV. [http ...]

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

De meest recente officiële openbare Europese epidemiologische gegevens dateren van oktober 2009 (ECDC Annual Epidemiological Report on Communicable Diseases in the European Union).
Les données épidémiologiques européennes officielles publiques les plus récentes datent de 2009 (European Centre for Disease Prevention and Control (ECDC) Annual Epidemiological Report on Communicable Diseases in the European Union).